Trends in antibacterial use in US academic health centers: 2002 to 2006.
about
Hospital Mortality in the United States following Acute Kidney InjuryEvaluation of regional antibiograms to monitor antimicrobial resistance in Hampton Roads, VirginiaUse of data envelopment analysis to quantify opportunities for antibacterial targets for reduction of health care-associated Clostridium difficile infection.Estimating Ten-Year Trends in Septic Shock Incidence and Mortality in United States Academic Medical Centers Using Clinical Data.Vancomycin-induced thrombocytopenia without isolation of a drug-dependent antibody.Use of International Classification of Diseases, Ninth Revision, Clinical Modification codes and medication use data to identify nosocomial Clostridium difficile infection.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensMeasurement of adult antimicrobial drug use in tertiary care hospital using defined daily dose and days of therapy.Deriving measures of intensive care unit antimicrobial use from computerized pharmacy data: methods, validation, and overcoming barriers.Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study.Stable susceptibility to aminoglycosides in an age of low level, institutional use.Appraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use.Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patientsImpact of an antibiotic restriction program on antibiotic utilization in the treatment of community-acquired pneumonia in a Veterans Affairs Medical Center.Does universal active MRSA surveillance influence anti-MRSA antibiotic use? A retrospective analysis of the treatment of patients admitted with suspicion of infection at Veterans Affairs Medical Centers between 2005 and 2010Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study.Genomic analysis of the emergence of vancomycin-resistant Staphylococcus aureusStatin use and the risk of Clostridium difficile in academic medical centres.In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureusImplementing a strategy for monitoring inpatient antimicrobial use among hospitals in the United States.Variability in antibiotic use at children's hospitals.Does doxycycline protect against development of Clostridium difficile infection?Targets for antibiotic and healthcare resource stewardship in inpatient community-acquired pneumonia: a comparison of management practices with National Guideline Recommendations.Long-term outcomes of an antimicrobial stewardship program implemented in a hospital with low baseline antibiotic use.Clinical Value of an Ambulatory-Based Antibiogram for Uropathogens in ChildrenInvestigating the Extremes of Antibiotic Use with an Epidemiologic FrameworkReduced Mortality Associated with Acute Kidney Injury Requiring Dialysis in the United States.Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosaImpact of antimicrobial stewardship in critical care: a systematic review.Antimicrobial stewardship programs: methods of operation and suggested outcomes.Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis.Evaluation of postprescription review and feedback as a method of promoting rational antimicrobial use: a multicenter intervention.Benchmarking antimicrobial drug use in hospitals.Management and prevention of ventilator-associated pneumonia caused by multidrug-resistant pathogens.An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.Time from onset of SIRS to antibiotic administration and outcomes after subarachnoid hemorrhage.Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.Oritavancin: A Long-Half-Life Lipoglycopeptide.
P2860
Q26744765-8BA54452-5F2C-426B-BE44-2AFE5043B4B5Q28649661-C521BAB8-1F37-40FF-B1CC-6268D04F9519Q30666603-0D5EBC75-6DD2-45E6-AED5-CE3A8611D382Q31117133-2EBA9050-6CAE-4169-90F7-5D4FB1133D9BQ33403804-3A0AF86B-0704-4BBC-92A3-611B3C6C355FQ33508665-3236550D-9BEA-47F2-990E-BB597108DE99Q33788308-B4904CAF-8F7C-423C-88E2-78BF123B1A8FQ33877785-0DFAAA30-6070-4220-8479-B40B91E63B5CQ33880773-78BD8514-54FA-41D2-9AAD-050957CA5935Q33925668-C5211EEF-E257-4DCE-B219-4E69DCDE0BFEQ33939064-97EE8003-BBB4-4A71-9BDC-0C6536C4ABFBQ34003193-EE53D4E6-00AE-4BAB-B0F8-424FDF78FAFCQ34057352-60446A98-0EE3-4498-9889-2D2059418E8FQ34336456-93AFCB17-CF29-4253-B49A-2B2FCBAB5B15Q34768097-09CBD2F9-0A6E-4213-A662-D05903E2EA78Q34974836-65509774-CEDE-48FE-B2BF-C2F2A47B5C09Q35936604-B247732C-BF62-4BFA-B5A7-568A84BE46FAQ36073633-19443563-1889-4F26-8BBE-95D179B8A352Q36117003-872A26F4-C91B-4D48-924B-BC9B78C2B1C4Q36171604-84169D03-5479-4D36-8B49-D1D11F36A1A6Q36281068-884F7BD1-BCE5-4437-9B44-4C003FE1DD7DQ36366551-FCD9CE90-1A5F-4380-83C9-B3918E6B18FAQ36379583-EA895F34-D37D-41FE-B70C-F4CF44095B5FQ36595082-E2E8ECC7-2255-4032-A154-72250D0D2197Q36813038-C1D39E58-EB5B-4C1F-A5A1-E45A343069FFQ36851116-626D5AC0-E1C7-4F82-9DF6-10DA25380A6DQ36933322-C2EC405B-B689-4274-A0E2-5B27DF6395F6Q36984517-CBF3117B-B859-4544-968F-563BBB066E70Q37190690-0ED69AC1-0C51-40C9-B161-8D8F2FF980F4Q37860821-88964B98-F33E-46C5-B04B-BEC3285D8BFCQ37965696-8E6B1862-60DF-409B-96E2-28901F2D5AFBQ37993714-B7660ED3-E154-411D-B497-EF10F62DF293Q37993717-2C1CA377-2DC3-4821-8CE0-1A76B79E11D2Q38003493-1CB4F6DE-E1CE-4270-8AFF-E3AA3210BD90Q38058355-EF298034-F594-4603-AA12-FA671FCF8FECQ38070154-49CDB6E2-94DC-46EC-A99E-CD57EF731693Q38120497-5229DAD3-0018-4A74-A4A0-8BD4C80F8909Q38286351-D29B7D5E-2BC1-4D35-8ABE-3A0A5C456A5BQ38409273-08A5C544-4CD9-423B-BD8F-3D716590EA05Q38434265-F0E9532D-C5B8-485C-885D-DC38B91A99A7
P2860
Trends in antibacterial use in US academic health centers: 2002 to 2006.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Trends in antibacterial use in US academic health centers: 2002 to 2006.
@en
Trends in antibacterial use in US academic health centers: 2002 to 2006.
@nl
type
label
Trends in antibacterial use in US academic health centers: 2002 to 2006.
@en
Trends in antibacterial use in US academic health centers: 2002 to 2006.
@nl
prefLabel
Trends in antibacterial use in US academic health centers: 2002 to 2006.
@en
Trends in antibacterial use in US academic health centers: 2002 to 2006.
@nl
P2093
P1476
Trends in antibacterial use in US academic health centers: 2002 to 2006.
@en
P2093
Amy L Pakyz
Conan MacDougall
Michael Oinonen
Ronald E Polk
P304
P356
10.1001/ARCHINTE.168.20.2254
P407
P577
2008-11-01T00:00:00Z